References
Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, Zhou ZK (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 29:2639–2644. https://doi.org/10.1007/s00198-018-4649-8
Driessen JH, van Onzenoort HA, Starup-Linde J, Henry R, Burden AM, Neef C, van den Bergh JP, Vestergaard P, de Vries F (2015) Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. https://doi.org/10.1007/s00223-015-0037-y
Driessen JH, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh J, Vestergaard P, Henry RM (2016) The use of incretins and fractures - a meta-analysis on population-based real life data. Br J Clin Pharmacol 83:923–926. https://doi.org/10.1111/bcp.13167
Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 6:260–266. https://doi.org/10.1111/1753-0407.12102
Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J (2014) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine 48:107–115. https://doi.org/10.1007/s12020-014-0361-4
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
BL reports research grants (institution) from Amgen and Novo Nordisk. BL serves on advisory boards for Amgen, Eli Lilly, and UCB and has received honoraria for lecturing from Amgen, Eli Lilly, UCB, and TEVA.
TH has received lecture fees from Eli Lilly, Amgen, and Astra-Zeneca. JS-L reports personal fees from Gilead Sciences Denmark and personal fees from Eli Lilly Denmark, outside the submitted work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hygum, K., Harsløf, T., Langdahl, B. et al. Glucagon-like peptide-1 receptor agonists and fracture risk—limitations to current knowledge. Osteoporos Int 30, 1709–1710 (2019). https://doi.org/10.1007/s00198-019-05013-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-019-05013-7